title: Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data.
abstract: BACKGROUND
  Cancer survival is a key measure of the effectiveness of health-care systems. Persistent regional and international differences in survival represent many avoidable deaths. Differences in survival have prompted or guided cancer control strategies. This is the first study in a programme to investigate international survival disparities, with the aim of informing health policy to raise standards and reduce inequalities in survival.
  
  
  METHODS
  Data from population-based cancer registries in 12 jurisdictions in six countries were provided for 2·4 million adults diagnosed with primary colorectal, lung, breast (women), or ovarian cancer during 1995-2007, with follow-up to Dec 31, 2007. Data quality control and analyses were done centrally with a common protocol, overseen by external experts. We estimated 1-year and 5-year relative survival, constructing 252 complete life tables to control for background mortality by age, sex, and calendar year. We report age-specific and age-standardised relative survival at 1 and 5 years, and 5-year survival conditional on survival to the first anniversary of diagnosis. We also examined incidence and mortality trends during 1985-2005.
  
  
  RESULTS
  Relative survival improved during 1995-2007 for all four cancers in all jurisdictions. Survival was persistently higher in Australia, Canada, and Sweden, intermediate in Norway, and lower in Denmark, England, Northern Ireland, and Wales, particularly in the first year after diagnosis and for patients aged 65 years and older. International differences narrowed at all ages for breast cancer, from about 9% to 5% at 1 year and from about 14% to 8% at 5 years, but less or not at all for the other cancers. For colorectal cancer, the international range narrowed only for patients aged 65 years and older, by 2-6% at 1 year and by 2-3% at 5 years.
  
  
  CONCLUSIONS
  Up-to-date survival trends show increases but persistent differences between countries. Trends in cancer incidence and mortality are broadly consistent with these trends in survival. Data quality and changes in classification are not likely explanations. The patterns are consistent with later diagnosis or differences in treatment, particularly in Denmark and the UK, and in patients aged 65 years and older.
  
  
  BACKGROUND
  Department of Health, England; and Cancer Research UK.
authors.affiliation: Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine, London, UK. michel.coleman@lshtm.ac.uk
authors.forename: M P
authors.initials: MP
authors.lastname: Coleman
authors.forename: D
authors.initials: D
authors.lastname: Forman
authors.forename: H
authors.initials: H
authors.lastname: Bryant
authors.forename: J
authors.initials: J
authors.lastname: Butler
authors.forename: B
authors.initials: B
authors.lastname: Rachet
authors.forename: C
authors.initials: C
authors.lastname: Maringe
authors.forename: U
authors.initials: U
authors.lastname: Nur
authors.forename: E
authors.initials: E
authors.lastname: Tracey
authors.forename: M
authors.initials: M
authors.lastname: Coory
authors.forename: J
authors.initials: J
authors.lastname: Hatcher
authors.forename: C E
authors.initials: CE
authors.lastname: McGahan
authors.forename: D
authors.initials: D
authors.lastname: Turner
authors.forename: L
authors.initials: L
authors.lastname: Marrett
authors.forename: M L
authors.initials: ML
authors.lastname: Gjerstorff
authors.forename: T B
authors.initials: TB
authors.lastname: Johannesen
authors.forename: J
authors.initials: J
authors.lastname: Adolfsson
authors.forename: M
authors.initials: M
authors.lastname: Lambe
authors.forename: G
authors.initials: G
authors.lastname: Lawrence
authors.forename: D
authors.initials: D
authors.lastname: Meechan
authors.forename: E J
authors.initials: EJ
authors.lastname: Morris
authors.forename: R
authors.initials: R
authors.lastname: Middleton
authors.forename: J
authors.initials: J
authors.lastname: Steward
authors.forename: M A
authors.initials: MA
authors.lastname: Richards
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001315:Australia / Q000453:epidemiology; D019985:Benchmarking; D001943:Breast Neoplasms / Q000401:mortality; D002170:Canada / Q000453:epidemiology; D015179:Colorectal Neoplasms / Q000401:mortality; D003718:Denmark / Q000453:epidemiology; D005260:Female; D006801:Humans; D015994:Incidence; D007391:International Cooperation; D015993:Life Tables; D008175:Lung Neoplasms / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009026:Mortality / Q000639:trends; D009369:Neoplasms / Q000453:epidemiology / Q000401:mortality*; D009664:Norway / Q000453:epidemiology; D010051:Ovarian Neoplasms / Q000401:mortality; D011786:Quality Control; D012042:Registries; D012107:Research Design; D015996:Survival Rate; D013548:Sweden / Q000453:epidemiology; D006113:United Kingdom / Q000453:epidemiology; D055815:Young Adult